MSB 5710
Alternative Names: MSB-5710Latest Information Update: 29 Apr 2021
At a glance
- Originator University of California, San Diego
- Developer MatriSys Bio
- Class Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Skin cancer
Most Recent Events
- 16 Mar 2021 Preclinical trials in Skin cancer in USA (Topical) (MatriSys Bio pipeline, March 2021)